Jae Park Explains CAR T-cell Therapy

Video

Jae Park, MD, Memorial Sloan Kettering Cancer Center, explains CAR T-cell therapy, which is currently being investigated in patients with acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma.

Jae Park, MD, Memorial Sloan Kettering Cancer Center, explains CAR T-cell therapy, which is currently being investigated in patients with acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma.

CAR T-cells are artificial T-cell receptors that are made by combining a domain from an antibody to the domain of a T-cell. This makes the therapy effective because it can signal and act like a T-cell and bind like an antibody, taking advantage of both bodies, Park explains. Also incorporating the T-cell allows the therapy to be a “living drug” that can grow and replicate, not limited by its determined half-life.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Photo of a woman with brown hair and a floral blouse
Photo of a woman with a blue border around the image
2 experts are featured in this series.
2 experts are featured in this series.
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Image of a woman with white hair in front of an Oncology Nursing News blue background
2 experts are featured in this series.
Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop
Related Content